For the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement

Ordering Information

Important Safety Information and Indications

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

OTIPRIO (ciprofloxacin otic suspension) 6% is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO

How to Order

We have partnered with select specialty distributors to help ensure access to OTIPRIO

Ordering information

Wholesaler/ Distributor Item Order Number Contact Information
ASD Specialty Healthcare* 46146 Tel #: 1-800-746-6273
Fax #: 1-800-547-9413
Email: asd.customerservice @asdhealthcare.com
Besse Medical 46146 Tel #: 1-800-543-2111
Fax #: 1-800-543-8695
Web Order URL: www.besse.com
Cardinal Health Specialty Distribution 5216924 Tel #: 1-866-677-4844
Fax #: 1-888-345-4916
Web Order URL: specialtyonline. cardinalhealth.com orderexpress. cardinalhealth.com
Henry Schein 124-8971 Tel #: 1-800-772-4346
Fax #: 1-800-329-9109
Web Order URL: www.henryschein.com /medical
McKesson Plasma and Biologics 3518339 Tel #: 1-877-625-2566
Fax #: 1-888-752-7626
Web Order URL: connect. mckesson.com
NDC# Product Unit Qty
69251-201-01 Each OTIPRIO carton contains 1 mL of 6% (60 mg/mL, w/v) ciprofloxacin in a 2 mL single-patient use glass vial fitted with a stopper not made with natural rubber latex One (1) box contains one single-patient use 2 mL vial

OTIPRIO vial and package

Additional support

  • For additional assistance, please call our Customer Service Center at 1-800-826-6411.
  • *For customers of AmerisourceBergen Corporation full-line wholesale division, OTIPRIO is available through ASD Healthcare and can be ordered using the PassPort ordering platform through AmerisourceBergen. The PassPort Item Number for OTIPRIO is 10162548.
  • For customers of Cardinal Health full-line wholesale division, OTIPRIO is available for purchase through Cardinal Health Specialty Distribution.
 
DISCLAIMER: This guide is intended solely for educational purposes regarding possible codes to report for use of OTIPRIO. The information provided contains general reimbursement information only and represents Otonomy’s understanding of current reimbursement policies as of January 1, 2017. Information should not be construed as legal advice nor is it advice about how to code, complete, or submit any particular claim for payment. Coding and reimbursement information is subject to change. Information provided is not intended to increase or maximize reimbursement by any payer.
Otonomy disclaims any responsibility for claims submitted by providers or physicians. The key in all coding and billing to payers is to be truthful and not misleading and make full disclosures to the payer about the product and the procedures associated with its use when seeking reimbursement for any product or procedure. It is the provider’s and physician’s responsibility to determine appropriate codes, charges, and modifiers, and to submit bills for services and products consistent with what was rendered as well as the patient’s insurer requirements. Third-party payers may have different coverage and reimbursement policies and coding requirements. Such policies can change over time. Providers are encouraged to contact third-party payers for each patient to verify specific information on their coding policies.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

OTIPRIO (ciprofloxacin otic suspension) 6% is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components of OTIPRIO.

WARNINGS AND PRECAUTIONS

Potential for Microbial Overgrowth: OTIPRIO may result in overgrowth of non-susceptible bacteria and fungi. If such infections occur, institute alternative therapy.

ADVERSE REACTIONS

Bilateral otitis media with effusion clinical trials: Adverse reactions (incidence at least 3%) with OTIPRIO vs sham were: nasopharyngitis (5% vs 4%), irritability (5% vs 3%), and rhinorrhea (3% vs 2%).

Acute otitis externa clinical trial: Adverse reactions (incidence at least 2%) with OTIPRIO vs sham were: ear pruritus (2% vs 2%), headache (2% vs 1%), otitis media (2% vs 1%), and ear discomfort (2% vs 0%).

USE IN SPECIFIC POPULATIONS

Pediatric Use: The safety and effectiveness of OTIPRIO in infants below six months of age have not been established for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement and acute otitis externa.

INDICATIONS AND USAGE

OTIPRIO (ciprofloxacin otic suspension) 6% is a fluoroquinolone antibacterial indicated for:

  • The treatment of pediatric patients (6 months of age and older) with bilateral otitis media with effusion undergoing tympanostomy tube placement
  • The treatment of acute otitis externa in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus